ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New Director

<< Previous

Bullboard Posts

Next >>

Comment by M101on Sep 01, 2021 11:46am

147 Views

Post# 33794421

RE:New Director

Seems good, but can someone qualified please join the dots for me?

"We have built the industry’s only platform for the tunable upregulation of genes. Our approach enables the efficient and systematic identification of gene specific regulatory RNA targets and generates bespoke oligonucleotide drug candidates to reach them."
https://www.camp4tx.com/reg-actuators/

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security